Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HGFKM
ADC Name
BGA2490
Synonyms
BGA2490
   Click to Show/Hide
Organization
BEIGENE, LTD. | BEIGENE SWITZERLAND GMBH
Drug Status
Investigative
Drug-to-Antibody Ratio
8.06
Structure
Antibody Name
BGA5384
  Antibody Info 
Antigen Name
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
  Antigen Info 
Payload Name
ADC-C3 Payload
  Payload Info 
Linker Name
BGA2490 Linker
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.19
nM
CVCL_1531
Lung adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.44
nM
CVCL_0434
Gastric adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.76
nM
CVCL_1384
Colon adenocarcinoma
Half Maximal Effective Concentration (EC50) 
21
nM
CVCL_0062
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.19 nM Positive CEA expression (CEA+++/++)
Method Description
NCI-H2122 cells were plated at a density of 2000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
In Vitro Model Lung adenocarcinoma NCI-H2122 cells CVCL_1531
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.44 nM Positive CEA expression (CEA+++/++)
Method Description
MKN45 cells were plated at a density of 5000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
In Vitro Model Gastric adenocarcinoma MKN45 cells CVCL_0434
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.76 nM Positive CEA expression (CEA+++/++)
Method Description
Ls147T cells were plated at a density of 5000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
In Vitro Model Colon adenocarcinoma Ls147T cells CVCL_1384
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 21 nM Negative CEA expression (CEA-)
Method Description
MDA-MB-231 cells were plated at a density of 2000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
References
Ref 1 Anti-CEA antibody drug conjugates and methods of use